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Modifications of biomaterial surface properties are employed to increase 
osteoblast differentiation and bone formation. Microtextured metallic surfaces promote 
osteoblast differentiation and high surface energy- achieved by controlling surface 
hydrocarbon contamination- increases osteoblast differentiation and peri-implant bone 
formation. Recombinant human bone morphogenic protein 2 (BMP2) is approved to 
induce bone formation in a number of applications. It is used clinically in combination 
with biomaterials to improve peri-implant bone formation and osseointegration. The 
amount of BMP2 that is required is large and inflammatory (swelling/seroma) and bone-
related (ectopic bone/bone resorption) complications have been reported after BMP2 
treatment. The aim of this study was to examine potential deleterious effects of BMP2 on 
the inflammatory environment and apoptosis of osteoblasts. 
Surface roughness and energy decreased pro-inflammatory interleukins and 
increased anti-inflammatory interleukins. In contrast, BMP2 abolished the surface effect, 
increasing pro-inflammatory interleukin (IL) 6, IL8, and IL17 in a surface roughness-
dependent fashion and decreasing anti-inflammatory IL10 on rough surfaces. 5Z-7-
Oxozeaenol and Dorsomorphin, but not H-8, blocked the effect of BMP2 on IL1A 
expression. There was an increase in expression of IL6 when treated with BMP2 for the 
control and H-8 groups, but both 5Z-7-Oxozeaenol and Dorsomorphin blocked the effect. 
Both 5Z-7-Oxozeaenol and H-8 blocked the effect of BMP2 on IL10 expression.  
     BMP2 treatment had little effect on apoptosis in human mesenchymal stem 
cells (MSCs). Exogenous BMP2 had no effect on TUNEL. Caspase-3 activity was 
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increased only at 200ng/ml BMP2. BAX/BCL2 decreased in MSCs treated with 50 and 
100ng/ml BMP2. In contrast, BMP2 increased caspase-3 activity and TUNEL at all doses 
in normal human osteoblasts (NHOst). BAX/BCL2 increased in NHOst treated with 
BMP2 in a dose-dependent manner. Cells treated with 200 ng/ml BMP2 had an 8-fold 
increase in BAX/BCL2 expression in comparison with untreated cells. Similarly, BMP2 
increased DNA fragmentation in NHOst cells. The BMP2-induced increase in DNA 
fragmentation was eliminated by 5-Z7-Oxozeaenol and Dorsomorphin. 
The results suggest that while surface features modulate an initial controlled 
inflammatory response, the addition of BMP2 induces a pro-inflammatory response. The 
effect of BMP2 on apoptosis depends on cell maturation state, inducing apoptosis in 
committed osteoblasts. BMP2 together with microtextured orthopaedic and dental 
implants may increase inflammation and possibly delay bone formation. Dose, location, 
and delivery strategies are important considerations in BMP2 as a therapeutic and must 








Bone morphogenetic proteins 
 Bone morphogenetic proteins (BMPs) were first described in 1965 by Marshall 
Urist as the active component of demineralized bone matrix able to induce ectopic bone 
formation. BMPs are members of the TGF-β growth factor superfamily (1). BMPs are 
generated by proteolytic cleavage of the transcribed preproproteins (2). After cleavage, 
mature BMPs are secreted from the cell and form homodimers or heterodimers to activate 
signaling (3, 4). BMPs transduce signals through membrane serine/threonine kinase 
receptors (5-7). These receptors, categorized as type I and type II receptors, have 
differential specificity for BMP ligands (8, 9). Dimers of type I receptors combine with 
dimers of type II receptors to transduce signaling. It has been demonstrated that the order 
of receptor recruitment and binding determines signaling (9). BMP binding to preformed 
complexes activates Smad signaling, while BMP-induced formation of heteromeric 
complexes activates non-canonical BMP signaling (9). Smads are intracellular signaling 
proteins that are categorized as either receptor-regulated Smads, common-partner Smad, 
or inhibitory Smads (5, 10). Type I BMP receptors phosphorylate Smad1/5/8. The 
activated Smad then complexes with common-partner Smad4, translocates to the nucleus, 
and initiates downstream signaling. In addition to this canonical Smad signaling, BMP 
signaling can also activate mitogen activated kinase signaling molecules (ERK1/2, p38, 
Jun N-terminal kinase) through activation of transforming growth factor β–activated 
kinase 1 (TAK1) and TAK1-binding protein (TAB) (6, 11, 12). 
 BMP signaling is required for multiple processes in embryonic and adult tissue 
formation and homeostasis (1, 13-15). BMP signaling controls mesoderm patterning, 
chondrogenesis and osteogenesis in skeletogenesis, cartilage and bone formation, and 
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limb development. In vitro, BMPs induce adipogenic, chondrogenic, and osteogenic 
differentiation of progenitor cells (16-18). BMP signaling also promotes patterning of 
craniofacial structures, and limb development. Programmed cell death, or apoptosis, is 
important in several of these processes. BMP2, BMP4, and BMP7 initiate apoptosis in 
the developing limb (19-21). While the effects of BMPs on apoptosis are clear, the 
controlling mechanisms in embryonic and adult processes remain to be elucidated. 
 Besides roles in development, BMP2 is essential in bone regeneration. In a mouse 
model, limb-specific deletion of BMP2 expression delayed endochondral bone formation 
and led to micro-fractures in animals by post-natal day 14 (22, 23). Recombinant BMP2 
and BMP7 (OP-1) are approved by the Food and Drug Administration for use in bone 
formation (24). BMP2 is used in fracture repair, anterior lumbar spinal fusions, alveolar 
ridge augmentation, and sinus lifts. Additionally, there is interest in combining BMP2 
with biomaterials to enhance bone formation around the implanted material. However, 
incidences of ectopic bone formation, swelling of soft tissue, and bone resorption have 
been reported with its use (25-27). 
Host-biomaterial Interaction 
 Biomaterials are defined as “natural or synthetic materials used to direct, 
supplement, or replace functions of living tissues” (28). These materials can be 
categorized as ceramic, polymeric, metallic, or composite/hybrid materials. Because of 
their biocompatibility, durability, and strength, metals such as stainless steel, cobalt-
chromium and alloys, and titanium and titanium alloys are frequently used for dental and 
orthopaedic biomaterial implants. The aim of these implants is direct apposition of bone 
to the biomaterial, termed osseointegration, while achieving maintenance and functional 
restoration of the existing bone. Titanium and titanium alloys possess material properties 
that make them advantageous for biomaterial applications. First, they spontaneously form 
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an oxide layer that provides corrosion resistance. Second, this oxide layer also provides 
biocompatibility to the implant. Finally, titanium is stronger than stainless steel, but much 
less dense, and has high fatigue resistance, making it appropriate in load-bearing 
orthopaedic and dental applications (29).  
 The interaction between the patient host tissue and the implant material 
determines the overall success of the implant. Although titanium is biocompatible, 
biological, physical, and chemical surface modifications have been employed to enhance 
osseointegration. Biological modifications such as tethering of adhesion motifs (RGD 
sequences), hydroxyapatite coatings, and bioactive proteins (including BMP2) have been 
investigated to encourage formation of bone around the implant. Physical and chemical 
modifications such as sandblasting, acid etching, oxidation, plasma spray, or 
combinations of these techniques, are applied to titanium biomaterials to alter surface 
chemistry, topography, and wettability. 
 The first event after implant placement is the attachment of blood and serum 
proteins to the implant surface. These interactions are regulated by material properties of 
the implant, including chemical composition, energy, and micro-nanotopography (30-32). 
The cells that attach to the implant surface do not directly interact with the material, but 
with this adsorbed protein layer (33, 34). Surface properties also control cell shape (35, 
36), which can effect gene transcription and cell response (37). In vitro, sand-
blasted/acid-etched titanium surfaces (SLA) or hydrophilic SLA (modSLA) induce 
osteoblasts maturation to a greater extent than cells cultured on smooth Ti or tissue 
culture polystyrene (TCPS) phenotype (36, 38, 39). In addition, osteoblasts cultured on 
SLA or modSLA secrete higher levels of autocrine or paracrine factures that regulate 
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osteogenesis (40), including prostaglandin E2, osteoprotegerin, transforming growth 
factor beta-1, Wnt5a, Dickkopf-1 and -2, and BMP2 (38, 41-45). Factors secreted by cells 
on microstructured Ti surfaces are also able to induce differentiation of mesenchymal 
stem cells in a co-culture model (46), indicating that paracrine regulation of distal cells is 
involved in osseointegration. Results of in vitro studies have been correlated with in vivo 
and clinical outcomes. SLA and modSLA implants have greater bone-to-implant contact 
and removal torque and faster healing than smooth Ti implants (47-52). However, 
whether surface properties modulate immune response is unclear. 
 After implant placement, the initial blood clot is remodeled by immune cells that 
mediate the wound healing process. Cytokines are pleotropic proteins that regulate the 
inflammatory response in an autocrine, paracrine, and endocrine fashion (53). Both innate 
and inflammatory responses can be triggered by biomaterial implantation. Inflammation 
typically resolves during the normal course of healing. However, if a chronic 
inflammatory environment is triggered, phagocytic immune cells can lead to structural 
and chemical implant damage and possibly result in implant failure (54, 55). Surface 
properties such as hydrophilicity (54) and the combination of roughness and 
hydrophilicity (56) affect macrophage and dendritic cell phenotype. This evidence 
suggests that surface properties can be tailored to affect immune response. However, it is 
not clear whether osteoblasts differentiating on the implant surface are also able to 





SPECIFIC AIMS  
The objective of this study is to characterize the effect of BMP2 on regulation of 
inflammatory interleukin production and its relation to titanium surface roughness, and to 
determine the effect of BMP2 on osteoprogenitor and osteoblast apoptosis and the 
potential mechanism of action. 
The overall hypothesis is that BMP2 will affect interleukin production and induce 
apoptosis in osteoblasts. 
Aim 1: Determine the effect of BMP2 on regulation of pro- and anti-inflammatory 
interleukins and relation to implant surface roughness  
Aim 1.1: Examine production of interleukins by osteoblasts cultured on 
microtextured titanium surfaces 
Aim 1.2: Examine the effect of BMP2 addition on interleukin production 
Aim 1.3: Determine BMP pathway involved in this effect using specific small 
molecule inhibitors of BMP signaling 
Aim 2: Determine the effect of BMPs on osteoprogenitor and osteoblast apoptosis and 
the potential mechanism of action 
Aim 2.1: Determine the effect of BMP2 on osteoprogenitor and osteoblast 
apoptosis 
Aim 2.2: Determine the role of Noggin on osteoblast apoptosis 




Biocompatibility of materials is an important consideration in the development of 
dental and orthopaedic implants, as this factor can greatly affect the success of the 
implant. Cells interact with the surface of the implant and these interactions dictate the 
response of the cells to the biomaterial and lead to osseointegration of the implant to the 
bone. Surface properties have been modified to increase osteoblast differentiation and 
bone formation. It has been shown that microtextured titanium surfaces promote 
osteoblast differentiation and that high surface energy, achieved by controlling surface 
hydrocarbon contamination, further increases osteoblast differentiation, maturation, and 
bone formation around implants (57, 58).  
Peri-implant osteogenesis requires net new bone formation. While stimulatory 
effects on osteoblast maturation are important, control of osteoclastic remodeling is also 
critical. Several studies have shown that osteoblasts contribute to this process by 
producing higher levels of osteoprotegerin (OPG) (40, 59), a decoy receptor for RANK 
ligand, thereby potentially reducing recruitment and activation of osteoclasts (59, 60). 
Inflammation processes play a role as well, particularly during the acute inflammatory 
response triggered in the early periods after injury (61, 62). Because of these initial 
inflammatory events, mesenchymal stem cells (MSCs) are recruited to the site of injury 
and begin tissue repair (63-65). Regulation of bone formation and subsequent bone 
remodeling can also be adversely affected by inflammatory responses, however, causing 
a shift from bone formation towards osteoclastogenesis and bone resorption that could 
impair osseointegration or lead to implant failure (66-69).  
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In vivo studies indicate that inflammation plays a role in osseointegration of 
metallic implants (70-73). We recently reported that dendritic cell maturation is reduced 
on microtextured Ti implant surfaces with high wettability (56), indicating that immune 
cells are sensitive to biomaterial surface properties. However, production of 
inflammatory cytokines is not limited to immune cells. Osteoblasts produce abundant 
cytokines to regulate inflammation, which include interleukins (IL).  
ILs can be classified as pro- or anti-inflammatory, although many can exhibit both 
types of behavior depending on the concentration. IL1 is one of the most well studied 
pro-inflammatory cytokines, existing in two isoforms (IL1α and IL1β) that function to 
activate macrophage and neutrophil responses (74, 75), promoting a TH1 immune 
response and suppressing the TH2 cell response. IL6, a pro-inflammatory cytokine that 
may also possess anti-inflammatory properties, stimulates B cells to produce 
immunoglobulins (76), promotes inflammation (77), and activates osteoclasts (78, 79). 
The cytokine IL7 regulates differentiation, proliferation, and survival of T lymphocytes 
(80). and studies have demonstrated that this pro-inflammatory factor plays an important 
role in inflammatory bone diseases (81), working together with other pro-inflammatory 
cytokines in the promotion of osteoclastogenesis (81), and activates target inflammatory 
genes such as chemokines, cytokines, and nitric oxide (82, 83). One of the most powerful 
anti-inflammatory cytokines, IL10 (84, 85), inhibits TH1 cytokines, monocytes, 
macrophages, and neutrophils (86), modulating acute inflammation and promoting 
humoral TH2 immune responses. 
Interleukins work together with many other cytokines in a complex network that 
determines the overall inflammatory response of the host to an implanted biomaterial. 
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However, determining the host-material interaction becomes more complicated as 
exogenous factors are introduced to enhance bone apposition. Bone morphogenetic 
proteins (BMPs) induce bone formation in development (1, 87). Recombinant human 
BMP2 (rhBMP2) is used clinically to induce bone formation in hard-to-heal fractures and 
defects, and is now being used in combination with metallic biomaterials to induce 
regeneration of bone around implants (88-91). Although this growth factor has been 
demonstrated to increase osteogenesis in the lumbar spine (92, 93), inflammatory 
complications including seroma and osteolysis have been reported to occur (25, 26, 94-
96).  There are a number of possible reasons for this, but the local concentration of BMP2 
may be a contributing factor (96). 
While cytokine production is necessary for immune responses to eliminate foreign 
pathogens, an imbalanced pro-inflammatory response after biomaterial implantation can 
produce extreme inflammation and possibly compromise biomaterial success. Little is 
known about the effects of the surface properties of an implant and BMP2 on the 
inflammatory microenvironment created by osteoblasts during osseointegration. The aim 
of the current study was to determine whether pro-osteogenic surface properties modulate 
the inflammatory interleukin response of osteoblasts in vitro and determine the effect 
exogenous BMP2 has on this process. 
MATERIALS AND METHODS 
Cell Culture 
Fifteen-millimeter Ti disks were prepared from 1mm thick sheets of grade 2 
unalloyed Ti and supplied to us by Institut Straumann AG (Basel, Switzerland). The 
methods used to produce smooth pretreatment (PT, Ra=0.08µm), rough sandblasted acid 
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etched (SLA, Ra=3.22µm), and modified SLA (modSLA, Ra=3.22µm) have been 
reported previously (36, 97). Hydrophilicity of the surfaces was calculated using 
advancing contact angles [PT (95.8°), SLA (139.80°), and modSLA (~0°)]. 
Human MG63 osteoblast-like osteosarcoma cells were obtained from the 
American Type Culture Collection (Rockville, MD). These cells are a progenitor cell 
model of osteoblast differentiation used in biomaterial studies, and have been previously 
demonstrated to increase markers of osteoblast maturation in response to Ti substrates 
with micron- and submicron-scale roughness and high surface energy (98, 99). MG63 
cells were plated on tissue culture polystyrene (TCPS) or Ti substrates at a density of 
10,000 cells per cm2. Cells were cultured in DMEM containing 10% fetal bovine serum 
(FBS) and 1% penicillin/streptomycin. All cells were cultured at 37°C and 100% 
humidity. 
Interleukin Expression 
IL mRNA was measured in cells cultured as described on TCPS or Ti substrates. 
At confluence on TCPS, cells on all surfaces were incubated with fresh medium for 12h 
and RNA harvested using a TRIzol® (Invitrogen, Carlsbad, CA) extraction method 
following manufacturer’s protocol. mRNA was quantified using a NanoDrop 
spectrophotometer (Thermo Scientific, Waltham, MA). RNA (500 ng) was amplified 
using reverse transcription (High Capacity cDNA Reverse Transcription kit, Applied 
Biosystems, Carlsbad, CA). Starting quantities of mRNA were determined using 
SybrGreen chemistry (Power SYBR® Green PCR Master Mix, Applied Biosystems) in a 
StepOne Plus imaging system (Applied Biosystems). MG63 cells grown on TCPS were 
used to generate a standard curve for each gene of interest and values for each sample 
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extrapolated. mRNA was measured for IL1A, IL1B, IL6, IL7, IL8, IL10, and IL17 
(sequences in Table 1) using gene specific primers (MWG Operon, Huntsville, AL). 
Osteocalcin mRNA (OCN) was measured as an indicator of osteoblast differentiation. All 
genes are presented as normalized to glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH).   
Table 2.1. Primer sequences used in real-time qPCR analysis 
mRNA Sequence Accession Number 
IL1A F TTT GAC GAC GCA CTT GTA GC NM_000575 
R GCC ATG AAA TGA CTC CCT CTC 
IL1B F TGG CAG AAA GGG AAC AGA AAG G NM_000576 
R AAC AAA AGG GCT GGG GAT TGG 
IL6 F GCA GAA AAC AAC CTG AAC CTT C NM_000600 
R ACC TCA AAC TCC AAA AGA CCA G 
IL7 F TCT TCT TCT GTG CTG GAG ATG  NM_000880 
R GGA CCT TGT TAT GCT GTT GC 
IL8 F GAC ATA CTC CCA AAC CTT TCC AC NM_000584 
R AAA CCT CTC CAC AAC CCT CTG 
IL10 F TTA TCT TGT CTC TGG GCT TGG NM_000572 
R GAA TGA AGT GGT TGG GGA ATG 
IL17A F TGG GGC AGA ACG AAC TTT AAG NM_002190 
R GGC GAA AAT GGT TAC GAT GTG 
MSX2 F CCT CTC CCT CTC CAC GAA G NM_002449.4
R TGC CTC CGC CTA CAG AAC 
OCN F GTG ACG AGT TGG CTG ACC NM_199173 
R TGG AGA GGA GCA GAA CTG G 
GAPDH F GCT CTC CAG AAC ATC ATC C NM_002046.3
R TGC TTC ACC ACC TTC TTG 
Interleukin Protein Production 
Cells were cultured as described on TCPS or Ti disks and at confluence on TCPS, 
cells on all surfaces were incubated with fresh medium for 24h. Cells were released from 
TCPS and Ti surfaces using two sequential incubations with 0.25% trypsin for 10 min at 
37°C and counted using a cell counter (Z2 Particle counter, Beckman Coulter, Fullerton, 
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CA). Cellular alkaline phosphatase specific activity was measured to verify cell response 
to the microstructured Ti surfaces. Briefly, alkaline phosphatase specific activity 
(orthophosphoric monoester phosphohydrolase, alkaline; E.C. 3.1.3.1) was determined in 
cell lysates using a colorimetric assay measuring the release of p-nitrophenol from p-
nitrophenylphosphate at 37°C (100). Levels of secreted cytokines IL1α, IL6, IL8, IL10, 
and IL17 were assayed in the conditioned medium using ELISA (R&D Systems DuoSet, 
Minneapolis, MN). Protein levels were normalized to total cell number. 
To determine the effect of BMP2 on interleukin production, cells were cultured as 
described on TCPS or Ti substrates. At confluence on TCPS, cells were incubated with 
fresh medium ± 40ng/ml rhBMP2 for 24 hours. ELISA assays were used to quantify the 
pro-inflammatory and anti-inflammatory cytokines in the conditioned medium. 
Effect of BMP Pathway on Interleukin Expression 
 BMP2 binds to tetramers of BMP receptors, initiating downstream signaling 
through canonical Smad signaling or non-canonical protein kinase A (PKA) or 
TAB/TAK1 signaling. To determine the BMP pathway involved in inflammatory 
cytokine expression, specific BMP pathway inhibitors were used. (5Z) -7-Oxozeaenol, a 
TAK1 inhibitor (101, 102), Dorsomorphin, an inhibitor of type I BMP receptors (ALK2, 
ALK3, ALK6) that prevents Smad phosphorylation (103-105), and H-8, a protein kinase 
A inhibitor (106-108), were purchased from EMD Chemicals (Gibbstown, NJ). Cells 
were cultured on modSLA substrates as described above. Cells were pre-incubated for 2 
hours with control media, 100 nM (5Z)-7-Oxozeaenol, 10 nM Dorsomorphin, or 1 µM H-
8 followed by treatment with inhibitor ± 40 ng/ml rhBMP2 for 12 hours. RNA was 
harvested and expression quantified as described above.  
Statistical Analysis 
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 Data presented are from one of two sets of experiments, with comparable results. 
Each data point is the mean ± SEM of six independent cultures. Data were analyzed by 
analysis of variance and significant differences between groups determined using 
Bonferroni’s modification of the Student’s t-test. P<0.05 was considered to be 
significant. 
RESULTS 
Effect of Surface Roughness on Interleukin Expression 
 mRNAs for osteocalcin increased in a surface roughness and energy dependent 
manner (Fig. 2.1A), confirming increased cell maturation. mRNAs for anti-inflammatory 
IL10 increased with increasing surface roughness and energy, with a 3-fold increase on 
modSLA in comparison to TCPS or PT (Fig. 2.1B). 
 
Figure 2.1. Effect of surface microstructure and energy on anti-inflammatory mRNA 
levels. MG63 cells were cultured on TCPS or Ti surfaces and expression of OCN (A) and 
IL10 (B) measured by real-time qPCR. *p<0.05, versus TCPS; # p<0.05, versus PT; $ 
p<0.05, versus SLA. 
 
 Expression of pro-inflammatory cytokines was also regulated by surface 
roughness and energy. IL1A expression was increased on rough surfaces (Fig. 2.2A). 
However, while IL1B expression was 1.5-times higher on the rough SLA surface than on 
TCPS or PT, levels on modSLA were similar to PT (Fig. 2.2B). IL6 expression decreased 
on SLA in comparison to TCPS or PT, but was lowest on modSLA (Fig. 2.2C). IL7 
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expression decreased on all titanium surfaces in comparison to TCPS (Fig. 2.2D). Levels 
were similar in cells grown on PT or modSLA surfaces, but were highest on SLA. 
Expression of IL8 (Fig. 2.2E) decreased on SLA and modSLA surfaces in comparison to 
TCPS or PT, with the lowest expression on modSLA substrates. However, mRNAs for 
IL17 decreased on rough SLA surfaces and were further lowered by culture on modSLA 
(Fig. 2.2F). 
Figure 2.2. Effect of surface microstructure and energy on pro-inflammatory interleukin 
mRNA levels in MG63 cells. MG63 cells were cultured on TCPS or Ti surfaces and 
expression of IL1A (A), IL1B (B), IL6 (C), IL7 (D), IL8 (E), and IL17 (F) measured by 
real-time qPCR. *p<0.05, versus TCPS; # p<0.05, versus PT; $ p<0.05, versus SLA. 
Effect of Surface Roughness on Interleukin Production 
 Cell number was lower on titanium surfaces than on TCPS, with further decreases 
on rough (SLA) and rough/hydrophilic surfaces (Fig. 2.3A). Alkaline phosphatase 
specific activity (Fig. 2.3B) increased in a roughness and surface energy-dependent 
manner (TCPS < PT < SLA < modSLA). These results confirm cell response to these 
materials as demonstrated previously (36, 45).  
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Figure 2.3. Effect of surface microstructure and energy on osteogenic differentiation of 
MG63 cells. MG63 cells were cultured on TCPS or Ti surfaces to confluence and cell 
number (A) and alkaline phosphatase specific activity (B) measured. *p<0.05, versus 
TCPS; # p<0.05, versus PT; $ p<0.05, versus SLA. 
 
 Cells on Ti had higher IL10 production than TCPS, but modSLA induced highest 
production of the anti-inflammatory IL10 (Fig. 2.4A). Surface roughness increased 
secreted IL1α by 100% in comparison to TCPS or PT surfaces, but levels on modSLA 
surfaces were 50% higher than SLA (Fig. 2.4B). Levels of secreted IL6 and decreased in 
a roughness and surface energy-dependent manner, with the lowest levels produced on 
modSLA surfaces (Fig. 2.4C). IL8 production was similar on TCPS and PT surfaces, but 
levels were lower on SLA, and lowest on modSLA (Fig. 2.4D). Secreted IL17 was lower 
on PT and SLA surfaces than on TCPS; however, levels were lowest on modSLA (Fig. 
2.4E). 
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Figure 2.4. Effect of surface microstructure and energy on interleukin production by 
MG63 cells. MG63 cells were cultured on TCPS or Ti surfaces and production of anti-
inflammatory IL10 (A) or pro-inflammatory IL1α (B), IL6 (C), IL8 (D), and IL17 (E) 
measured in the conditioned media. *p<0.05, versus TCPS; # p<0.05, versus PT; $ 
p<0.05, versus SLA. 
 
Effect of Bone Morphogenetic Protein-2 on Interleukin Production 
 BMP2 treatment had no effect on cell number on the surfaces examined (Fig. 
2.5A). Alkaline phosphatase specific activity was higher in BMP2 treated cells on SLA 
surfaces than in untreated cells (Fig. 2.5B). 
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Figure 2.5. Effect of BMP2 on MG63 differentiation on microstructured Ti surfaces. 
MG63 cells were cultured on TCPS or Ti surfaces. At confluence, cells were treated with 
medium (control) or 40 ng/ml rhBMP2 for 24 hours and cell number (A) or alkaline 
phosphatase specific activity (B) measured. *p<0.05, versus TCPS; # p<0.05, versus PT; 
$ p<0.05, versus SLA; %p<0.05, versus control. 
 
 The increase in anti-inflammatory IL10 seen in cells culture on hydrophilic rough 
surfaces was abolished by BMP2 treatment (Fig. 2.6A). However, the increase in IL1α 
production by cells on rough surfaces was enhanced by BMP2 treatment (Fig. 2.6B). 
While culture on rough or high-energy rough surfaces decreased production of IL6 and 
IL8, treatment with BMP2 reversed this effect (Fig. 2.6C, 2.6D). Addition of BMP2 to 
cells on rough Ti caused a 100% increase in IL17 production in comparison to untreated 
cells (Fig. 2.6E). 
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Figure 2.6. Effect of BMP2 on inflammatory interleukin expression in MG63 cells 
cultured on microstructured Ti surfaces. MG63 cells were cultured on TCPS or Ti 
surfaces. At confluence, cells were treated with medium (control) or 40 ng/ml rhBMP2 
for 12 hours and mRNA levels of IL10 (A), IL1α (B), IL6 (C), IL8 (D) measured. 
*p<0.05, versus TCPS; # p<0.05, versus PT; $ p<0.05, versus SLA; %p<0.05, versus 
control. 
Mechanism of BMP2 Effect 
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 Treatment with BMP2 increased expression of MSX2, a factor that is transcribed 
after induction of BMP2 signaling (Fig. 2.7A). Treatment with Dorsomorphin, but not 
5Z-7-Oxozeaenol or H8, abolished this effect. All three inhibitors abolished the effect of 
BMP2 treatment on expression of IL10 (Fig. 2.7B). Increased expression of IL1A, IL6, 
and IL17 after BMP2 treatment was blocked with 5Z-7-Oxozeaenol and Dorsomorphin, 
but not H8 (Fig. 2.7B, 2.7C, 2.7F). BMP2 induced upregulation of IL8 expression was 
inhibited by both all three inhibitors (Fig. 2.7E). 
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Figure 2.7. BMP pathway modulation of inflammatory microenvironment produced by 
MG63 cells on microstructured Ti surfaces. MG63 cells were cultured on modSLA 
surfaces. Cells were treated with inhibitors targeting specific BMP signaling pathway 
components TAB/TAK (5Z-7-Oxozeaenol), Smad (Dorsomorphin), or PKA (H-8) in the 
presence or absence of 40 ng/ml rhBMP2. Levels of MSX2 (A), IL10 (B), IL1A (C), IL6 
(D), IL8 (E), and IL17 (F) mRNA were measured 12 hours after treatment. *p<0.05, 




An inflammatory response is necessary for osseointegration (73), but must occur 
in a coordinated series of events to prevent skewing the response from bone formation to 
bone resorption. In the current study, we examined the effect of Ti surface properties to 
modulate inflammatory interleukin production by osteoblasts. The results show that both 
surface topography and energy affect interleukin gene expression and protein levels in 
MG63 cells. Moreover, these effects are altered by rhBMP2 through TAB/TAK 
signaling.  
MG63 cells had higher IL1A and IL1B expression on rough and hydrophilic 
rough Ti surfaces and produced higher levels of these proteins. Both IL1α and IL1β are 
pro-inflammatory cytokines; however, they may play other roles as well. MSCs treated 
with IL1β exhibit an osteoblastic phenotype, including formation of Alizarin red positive 
nodules (109). Moreover, delivery of IL1β during the first 72 hours after fracture sped 
healing in an in vivo model (110). In addition, IL1β expression is increased in bone 
during fracture healing (111).  Thus, an increase in these cytokines at low concentration 
is consistent with enhanced bone healing. 
In contrast to the stimulatory effects of the microtextured surfaces on osteoblast 
production of IL1α and IL1β, the cells on these surfaces exhibited reduced expression 
and secretion of other inflammatory cytokines, such as IL6. IL6 induces bone resorption 
by increasing osteoclast activity (79, 112) and levels of this interleukin are increased in 
aseptic loosening (113-115). In vivo, the reduction in IL6 may help increase peri-implant 
bone formation by reducing osteoclast activity.   
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Similarly, rough surfaces and high surface energy significantly reduced IL8 and 
IL17 expression and levels. IL8 is a powerful recruiter of neutrophils and is present in 
high levels in areas of polymorphonuclear infiltration (116) and in prostate cancer-
induced osteolytic lesions (117). IL17 activates matrix metalloproteinases in MC3T3-E1 
osteoblasts, causing increased matrix degradation (81). There is evidence that IL17 
modulates the OPG-RANKL balance, increasing osteoclastogenesis and inducing bone 
remodeling (118, 119).  
Importantly, the anti-inflammatory cytokine IL10 was increased on rougher 
surfaces, an effect more robust with increased surface energy. IL10 inhibits NF-κB and 
suppresses production of pro-inflammatory cytokines by monocytes and macrophages 
(120, 121). This suggests that rougher surfaces, particularly on modSLA where 
hydrocarbon deposition is controlled, promote an anti-inflammatory response. The results 
demonstrate that cells on microstructure Ti surfaces secrete factors to modulate the bone 
formation process, and this effect is enhanced on rough, high-energy surfaces. 
In addition to direct effects on bone formation, it has also been shown that surface 
properties can affect other parameters that may affect implant success, including response 
of immune system cells to the biomaterial. Hydrophilic rough surfaces were found to 
support an immature dendritic phenotype while smooth surfaces enhanced dendritic cell 
maturation (56). Macrophages cultured on the same hydrophilic rough surfaces expressed 
lower levels of pro-inflammatory cytokines than cells on smooth substrates (122). Other 
studies have demonstrated that macrophages regulate inflammatory cytokines in response 
to changes in surface chemistry and topography (123-125). Taken together, surface 
properties directly control the inflammatory microenvironment by created by osteoblasts 
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and activation of immune cells, suggesting that this immuno-modulation may contribute 
to faster healing seen clinically in modSLA implants.  
In our study, administration of BMP2 to osteoblasts cultured on microstructured 
Ti implants increased pro-inflammatory, pro-osteoclastogenic interleukins and decreased 
the anti-inflammatory IL10. It is important to note that the effect of BMP2 was not 
observed on TCPS, a material commonly used for in vitro studies, but that BMP2 had a 
strong synergistic effect on roughness and energy. Interestingly, treatment with BMP2 
induced the opposite effect in cytokine profile in comparison to surface roughness and 
energy alone. BMPs are important in bone formation, and induce chondrogenic and 
osteogenic commitment of progenitor cells (87).  
Recombinant human BMP2 is one of two clinically available BMPs approved for 
use. While this morphogen has been demonstrated to induce bone formation, there have 
been reports of adverse effects including ectopic bone formation, osteolysis, and seroma 
formation (25, 26, 126). In animal models of inflammation, soft tissue inflammation was 
seen as early as 3 hours after subcutaneous implantation of rhBMP2, an effect dependent 
on protein dose (127, 128). The same study found increases in levels of secreted IL6. 
Studies have demonstrated that BMP2 upregulates IL6 in normal human osteoblasts, 
confirming the present results (129). Interestingly, in the dose used in our study, the 
increase in pro-inflammatory interleukin secretion came with only small gains in 
osteoblast maturation.  
 In our study, the TAB/TAK1 inhibitor (5Z)-7-Oxozeaenol blocked BMP2 induced 
IL6 expression. TAK1 has been demonstrated to mediate IL-6 expression during cyclic 
stress in osteoblasts (130). In addition, TAK1 silencing decreases the pro-inflammatory 
environment in a mouse inflammatory model (131). The inflammatory environment 
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Taken together, the results suggest surface roughness and energy modulate the 
initial inflammatory response, increasing anti-inflammatory interleukins and reducing 
pro-inflammatory interleukins. Surfaces known to induce osteoblast differentiation also 
modulate interleukin production. The control of interleukins production and other 
inflammatory processes by surface features may have a major role in bone healing and 
osseointegration. However, BMP2 treatment during orthopaedic and dental titanium 
implant insertion may produce adverse effects through TAB/TAK signaling by reversing 
the surface effect on the inflammation process, increasing pro-inflammatory interleukins, 





 Bone morphogenetic proteins (BMPs) are members of the transforming growth 
factor-β (TGF-β) super family (7), and a subset of BMPs possess the ability to induce 
bone and cartilage formation and enhance osteogenesis (132, 133). BMP2 is used 
clinically to induce bone formation in challenging bone defects in orthopaedics and 
dentistry (134). However, incidences of complications have been reported in orthopaedic 
applications including soft tissue swelling, ectopic bone formation, and even resorption 
of adjacent vertebral bodies (25, 135).  
 BMP2 must form homodimers or heterodimers to activate the BMP signaling 
pathway (4). The dimer then binds to a complex of four transmembrane receptors, 
consisting of two BMP type I receptors and two BMP type II receptors (7, 136), and one 
of three signaling pathways is initiated depending on the conformation of receptors upon 
ligand binding (9). In the first, BMP type I receptors phosphorylate Smad1, Smad5, or 
Smad8. This Smad then associates with Smad4 and the complex translocates to the 
nucleus and activates transcription of downstream genes (6, 137). Alternatively, p38 or 
JNK mitogen-activated protein kinase (MAPK) signaling can be initiated by TGF-β1 
activated kinase-1 (TAK-1) and TAK1 binding protein (TAB) (138, 139). Finally, protein 
kinase A (PKA) can be activated (140, 141), potentially leading to ERK1/2 MAPK 
activation. BMP signaling is regulated extracellularly by soluble inhibitors such as 
Noggin, Gremlin, Cerberus, and Chordin, which physically bind to BMPs, preventing 
their dimerization or receptor binding, inhibiting transduction of downstream signaling 
(2, 142).  
 BMPs induce cartilage and bone formation both during embryonic development 
and post-natally (13, 14) and they regulate other developmental and adult processes 
including cell growth and differentiation (15, 143, 144), as well as apoptosis (145-148). 
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Control of apoptosis during development ensures proper tissue morphogenesis. For 
example, BMP2 regulates fibroblast growth factor signaling to induce apoptosis in the 
apical ectodermal ridge during limb formation (149). In the chick limb bud, both BMP2 
and BMP4 are expressed in the anterior, posterior, and interdigital necrotic zones prior to 
apoptosis (150). However, there is limited evidence about the effects of BMP2 on 
apoptosis in adult osteoprogenitor cells or in committed osteoblasts.   
 Given the effects seen following the clinical use, the aim of this study was to 
characterize the effect of BMP2 on apoptosis of osteoprogenitor cells and osteoblasts, 
and the role of soluble BMP antagonist Noggin on this process, and lastly the BMP 
pathway used to induce apoptosis. 
MATERIALS AND METHODS 
Cell Culture 
The effect of BMP2 on apoptosis was examined in osteoprogenitor cells (MSCs), 
immature osteoblasts (MG63 cells), and mature osteoblasts (NHOst cells). Human bone 
marrow-derived mesenchymal stem cells (MSCs) were purchased from Lonza 
Biosciences (Walkersville, MD) and cultured in Mesenchymal Stem Cell Growth Media 
(MGSCGM, Lonza Biosciences). Human MG63 cells (American Type Culture 
Collection, Manassas, VA) were cultured in Dulbecco’s modification of Eagle’s Medium 
(cellgro®, MediaTech, Manassas, VA) supplemented with 10% fetal bovine serum 
(Gibco, Carlsbad, CA) and 1% penicillin-streptomycin (Gibco). Normal human 
osteoblasts (NHOst cells, Lonza) were cultured in Osteoblast Growth Media (Lonza). For 
all experiments, cells were plated at a density of 10,000 cells/cm2 and cultured at 37°C, 
5% CO2, and 100% humidity. Media were changed 24 hours after plating and every 48 
hours thereafter until cells reached confluence. 
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 Recombinant human BMP2 (R&D Systems, Minneapolis, MN) was reconstituted 
in sterile 4 mM HCl containing 0.1% bovine serum albumin to a stock concentration of 
100 µg/ml. The stock was diluted to final concentrations in culture medium. At 
confluence, cells were treated with 50, 100, or 200 ng/ml BMP2 unless noted otherwise. 
Proteome Profiler Array 
 The effect of BMP2 on osteoblast apoptosis was investigated using a Human 
Apoptosis Proteome Profiler Array (R&D Systems), which examined changes in 35 
apoptosis-related proteins. Confluent cultures of NHOst cells were treated with 200 ng/ml 
BMP2 for 6 hours. After incubation, cells were lysed and analyzed by modified Western 
blot. Membranes were imaged by chemiluminescence (VersaDoc, Bio-Rad, Hercules, 
CA) and changes in proteins determined by densitometry (QuantyOne, Bio-Rad). 
Caspase-3 
 Cells were treated with BMP2 as described for 6 hours and assayed for caspase-3 
activity using a commercial kit (R&D Systems) following manufacturer’s instructions. 
Briefly, cell monolayers were lysed in cold lysis buffer for 10 minutes at 4°C, and the 
cell lysates centrifuged at 10,000g for 1 minute. The resulting supernatant was combined 
with 2x reaction buffer and DEVD-pNA substrate and incubated at 37°C for 2 hours. 
Absorbance at 405 nm was determined using a microplate reader (VersaMax, Molecular 
Devices, Sunnyvale, CA). 
BAX/BCL2 mRNA Levels 
 Cells were treated with BMP2 for 12 hours. RNA was isolated using TriZOL® 
(Invitrogen, Carlsbad, CA) and was quantified (Nanodrop Spectrophotometer, Thermo 
Scientific, Waltham, MA). 250 ng of RNA was used to synthesize cDNA libraries (High 
Capacity cDNA Reverse Transcription kit, Applied Biosystems, Carlsbad, CA). Levels of 
mRNA were quantified with real-time quantitative PCR (StepOnePlus, Applied 
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Biosystems) using gene-specific primers (Table 1) and Power SybrGreen® Master Mix 
(Applied Biosystems). Starting mRNA quantities were determined by standard curve 
method. Levels of mRNA are presented as a ratio of BAX to BCL2. 
Table 3.1: Primer sequences used in real-time qPCR analysis 












Total p53 Levels 
 Total p53 levels were determined in cells 24 hours after treatment using a 
sandwich ELISA (Human Total p53 DuoSet® IC, R&D Systems). After treatment, 
monolayers were rinsed with PBS and lysed [PBS containing 1 mM EDTA, 0.5% 
TritonTM X-100, 10 mM NaF, 150 mM NaCl, 20 mM β-glycerophosphate, 1 mM 
dithiothreitol, 10 µg/ml leupeptin, 10 µg/ml pepstatin, 3 µg/ml aprotinin]. Lysates were 
centrifuged at 2000g for 5 minutes and the supernatant assayed for total p53 following 
manufacturer’s instructions. Results were normalized to total protein content (Pierce 
600nm Protein Assay, Thermo Scientific). 
DNA Fragmentation 
TUNEL Assay 
 DNA fragmentation was assessed by colorimetric terminal deoxynucleotidyl 
transferase (TdT)-mediated dUTP nick end labeling (TUNEL, TiterTACS™ in situ 
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Microplate TUNEL Assay, R&D Systems). Confluent cultures were treated for 24 hours. 
Media were removed, and cells were fixed with 3.7% sucrose-buffered formaldehyde and 
processed following manufacturer’s instructions. Absorbance at 450 nm was determined 
using a microplate reader. 
Radiometric Assay 
 At 60% confluence, cells were incubated with 1 µCi/ml 3H-thymidine (Perkin 
Elmer, Waltham, MA). At confluence, cultures were treated for 24 hours with BMP2. 
Cells were lysed [10mM Tris-HCl, 1mM EDTA, 0.2% Triton X-100] and subjected to 
three freeze-thaw cycles. Intact DNA was separated from fragmented DNA by 
ultracentrifugation at 13,000g for 15 minutes. Intact DNA (pellet) and fragmented DNA 
(supernatant) were counted by liquid scintillation counting (Beckman Coulter). Results 
are presented as percent fragmented DNA/total DNA. 
Noggin Expression 
 Since soluble inhibitors regulate the actions of BMPs, we wanted to determine the 
effect of BMP2 treatment on mRNA levels of NOG, one of the most powerful inhibitors 
of BMPs. Cells were treated with BMP2 as described. Levels of mRNA for NOG were 
determined after 12 hours as described above and are presented as normalized to mRNA 
levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
Noggin Silencing 
 shNOG-MG63 cells were examined to determine the role of Noggin in osteoblast 
apoptosis. MG63 cells silenced for Noggin (shNOG-MG63) were generated using 
lentiviral shRNA transduction particles (NM_005450, TRCN0000058563, Mission®, 
Sigma Aldrich, St. Louis, MO). MG63 cells were plated at 20,000 cells/cm2 and cultured 
overnight in full medium. Particles were added to the cells at a multiplicity of infection of 
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7.5 in full medium supplemented with 8 µg/ml hexadimethrine bromide (Sigma Aldrich) 
and incubated for 18 hours. After incubation, transduced cells were selected with full 
medium containing 0.25 µg/ml puromycin. The resulting cell line had a 70% reduction in 
NOG mRNA levels as determined by real-time qPCR and 72% reduction in secreted 
Noggin as determined by ELISA (data not shown). 
BMP2 Signaling Pathway 
Confluent cultures of NHOst cells were pre-treated for one hour with inhibitors of 
BMP2-dependent signaling pathways. 5Z-7-oxozeaenol (100 nM) was used to inhibit 
TAB/TAK1 signaling (101); dorsomorphin (10 nM) was used to inhibit Smad signaling 
(104, 105); H-8 (1 µM) was used to inhibit PKA signaling (151). All inhibitors were 
purchased from EMD Chemicals (San Diego, CA). BMP2 was added to the media 
containing the inhibitor to a final concentration of 200 ng/ml. Cells were incubated and 
assayed as described above. 
Statistical Analysis 
 Data are presented as mean ± SEM of six independent cultures per variable. Data 
were first examined by analysis of variance (ANOVA) and significant differences 
between groups were determined using Bonferroni’s modification of Student’s t-test. 
P<0.05 was considered to be significant. 
RESULTS 
The results of the proteome profiler array showed that of the 35 apoptosis-related 
proteins assessed (Fig. 3.1A), 9 proteins were significantly higher and 5 proteins were 
lower in BMP2-treated NHOst cells than in untreated cells (Fig. 3.1B). Levels of pro-
apoptotic proteins such as Bad, Bax, pro-caspase-3, and phosphorylated p53 (Ser 15) 
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were increased more than 20% in NHOst cells treated with BMP2 than in control cells 
(Fig. 3.1B). Anti-apoptotic markers Bcl-x, Omi, Livin, and XIAP were 25% lower in 
BMP2-treated NHOst cells than in untreated cultures (Fig. 3.1B).  
 
 
Figure 3.1. Effect of BMP2 treatment on apoptotic proteins in NHOst cells. Confluent 
cultures of NHOst cells were treated for 6 hours with BMP2. Cell lysates were analyzed 
by modified Western blot for levels of 32 proteins known to be involved in apoptosis and 
densitometry analysis performed (A), and proteins with more than 15% changes after 
BMP2 treatment identified (B). 
 
The effect of BMP2 on apoptosis varied with cell type. MSCs treated with 200 
ng/ml BMP2 exhibited a small increase in caspase-3, with no effect at lower doses (Fig. 
3.2A). Addition of BMP2 increased total p53 at all concentrations (Fig. 3.2C), but had no 
effect on BAX/BCL2 (Fig. 3.2B) or TUNEL (Fig. 3.2D). In MG63 cells, addition of 100 
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or 200 ng/ml BMP2 increased caspase-3 (Fig. 3.3A). However, BAX/BCL2 (Fig. 3.3B) 
and p53 (Fig. 3.3C) were only increased by 200 ng/ml BMP2. BMP2 had no effect on 
TUNEL in MG63 cells at the doses examined (Fig. 3.3D).  
 
 
Figure 3.2. Effect of BMP2 on mesenchymal stem cell apoptosis. MSCs were cultured 
until they reached confluence. Cells were treated with 50, 100, or 200 ng/ml BMP2 and 
Caspase-3 (A), BAX/BCL2 (B), total p53 (C), and TUNEL (D) measured. *p< 0.05, 




Figure 3.3. Effect of BMP2 on MG63 cell apoptosis. MG63 cells were cultured until they 
reached confluence. Cells were treated with 50, 100, or 200 ng/ml BMP2 and Caspase-3 
(A), BAX/BCL2 (B), total p53 (C), and TUNEL (D) measured. *p< 0.05, versus control; 
#p< 0.05, versus 50 ng/ml BMP2; $p< 0.05, versus 100 ng/ml BMP2. 
 
In contrast, BMP2 significantly increased caspase-3 in NHOst cells at all doses 
examined (Fig. 3.4A). BAX/BCL2 was increased after BMP2 treatment in a dose-
dependent manner, with a 7-fold increase after 200 ng/ml BMP treatment (Fig. 3.4B). 
Levels of p53 were higher in 100 ng/ml and 200 ng/ml treated cultures than control 
cultures (Fig. 3.4C). TUNEL was increased in cultures treated with 200 ng/ml BMP2 
(Fig. 3.4D), and this was confirmed by a 50% increase in percent fragmented DNA (data 




Figure 3.4. Effect of BMP2 on normal human osteoblast apoptosis. NHOst cells were 
cultured until they reached confluence. Cells were treated with 50, 100, or 200 ng/ml 
BMP2 and Caspase-3 (A), BAX/BCL2 (B), total p53 (C), and TUNEL (D) measured. 
*p< 0.05, versus control; #p< 0.05, versus 50 ng/ml BMP2; $p< 0.05, versus 100 ng/ml 
BMP2. 
 
Noggin expression was regulated by BMP2 in all cell types examined. In MSCs, 
NOG was 1.5-fold higher than control after BMP2 treatment, but decreased with 
increasing BMP2 dose (Fig. 3.5A). In MG63 cells, treatment with BMP2 induced a 
greater than 2-fold increase in NOG mRNA levels, an effect that increased with increased 
BMP2 dose (Fig. 3.5B). A similar effect was seen in NHOst, with a 3-fold increase in 




Figure 3.5. Effect of BMP2 treatment on NOG mRNA levels. Confluent cultures of 
MSCs (A), MG63 cells (B), and NHOst (C) were treated for 12 hours with 50, 100, or 
200 ng/ml BMP2 and levels of mRNA for NOG measured by real-time qPCR. *p< 0.05, 
versus control; #p< 0.05, versus 50 ng/ml BMP2; $p< 0.05, versus 100 ng/ml BMP2. 
 
Reduced Noggin expression resulted in increased expression of apoptotic markers 
and increased apoptosis. shNOG-MG63 cells had higher levels of apoptotic markers than 
wild type MG63 cells throughout the culture period. Wild type MG63 cells exhibited 
time-dependent increases in MTT activity (Fig. 3.6A). In contrast, shNOG-MG63 cells 
had increased MTT levels until day 5, when cells underwent apoptosis and MTT was 
reduced to 20% of levels seen in control (Fig. 3.6A). Caspase-3 was higher in shNOG-
MG63 cells at days 2, 3, and 4 than in wild type MG63 cells (Fig. 3.6B). BAX/BCL2 was 
also 100% higher in shNOG-MG63 cells at day 2 and 4 than in MG63 cells (Fig. 3.6C). 
shNOG-MG63 cells had higher TUNEL than MG63 cells at all times examined (Fig. 
3.6D). TUNEL was 100% higher in shNOG-MG63 cells at day 2 and 200% higher at day 





Figure 3.6. Effect of NOG silencing on MG63 cell apoptosis. MG63 and shNOG-MG63 
cells were harvested at various time points after plating. Caspase-3 (A), BAX/BCL2 (B), 








The increased apoptosis in shNOG-MG63 cells was enhanced by BMP2. MG63 
cells treated with 200 ng/ml BMP2 had a 25% increase in caspase-3; shNOG-MG63 cells 
had a higher baseline level of caspase-3, which was increased 25% by addition of BMP2 
(Fig. 3.7A). Likewise, BAX/BCL2 increased in MG63 cells treated with BMP2. Baseline 
BAX/BCL was higher in shNOG-MG63 cells and was synergistically increased by 
exogenous BMP2 (Fig. 3.7B).  
 
 
Figure 3.7. Effect of NOG silencing on BMP2-induced MG63 cell apoptosis. MG63 and 
shNOG-MG63 cells were treated with 200 ng/ml BMP2. Caspase-3 (A) and BAX/BCL2 
(B) were assessed. *p< 0.05, versus control; #p< 0.05, versus MG63 cells. 
 
 The effect of BMP2 on apoptosis was via a Smad-dependent signaling pathway. 
In NHOst cells, the stimulatory effect of 200 ng/ml BMP2 on caspase-3 activity was 
blocked by dorsomorphin, but not by 5Z-7-oxozeaenol or H-8 (Fig. 3.8A). Likewise, only 
dorsomorphin blocked the BMP2-induced increase in BAX/BCL2 (Fig. 3.8B). However, 
increased DNA fragmentation after BMP2 treatment was inhibited by both dorsomorphin 




Figure 3.8. Effect of BMP pathway inhibition on BMP2-induced NHOst apoptosis. 
Confluent cultures of NHOst were pre-treated with inhibitors to TAB1/TAK (5Z-7- 
Oxozeaenol, Ox), Smad (Dorsomorphin, DM), or PKA (H8) before treatment with 200 
ng/ml BMP2. Caspase-3 (A), BAX/BCL2 (B), and DNA fragmentation (C) were 
measured. #p< 0.05, versus untreated cells. 
DISCUSSION 
This study demonstrates that BMP2 modulates apoptosis in a cell-dependent 
manner. In MSCs, treatment with this morphogen had only small effects on apoptotic 
signaling. The immature osteoblast MG63 cells were sensitive to treatment with BMP2, 
but only at the highest dose used in our study. However, in NHOst cells, BMP2 induced 
apoptosis in a dose-dependent manner, an important fact given the exceedingly high 
doses used clinically.  
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BMP2 had little effect on apoptosis in MSCs in our study. BMPs are known to 
induce stem cell differentiation into chondrocytes, osteoblasts, and adipocytes in a dose-
dependent manner (152). Moreover, several studies have indicated that BMP signaling is 
also required for maintenance of the stem cell niche and MSC survival (153, 154). This 
evidence suggests that BMPs affect maintenance and differentiation, but not apoptosis, in 
MSCs, in agreement with the results of our study. 
Differential regulation of BMP2 effects were seen in cells committed to the 
osteoblast lineage. BMP2 increased BAX/BCL2, caspase-3, and TUNEL in immature 
osteoblast-like MG63 cells, confirming results using other immature osteoblast cell lines 
(148, 155). However, this effect was only at the highest dose tested. In committed 
osteoblasts, the effect was more robust, and occurred at lower doses. These observations 
suggest that the effect of BMP2 on osteoblast apoptosis is dependent on maturation state. 
In addition to up-regulating apoptotic markers, BMP2 down-regulated anti-apoptotic 
markers. In NHOst, anti-apoptotic Bcl-x was lower in cells treated with BMP2 than in 
untreated cells, confirming results seen in myeloma cells (147) and gastric cancer cells 
(146). Taken together, this emphasizes that the effect of BMP2 on cell apoptosis is 
conserved among cells of diverse origins, particularly those that are terminally 
differentiated.  
BMPs are tightly regulated intracellularly by Smads (156) and extracellularly by 
diverse families of soluble inhibitors, including Cerberus, Twisted gastrulation, Chordin, 
Crossveinless, and Noggin (142). The present study demonstrates that Noggin, a 
powerful inhibitor of BMP signaling, was regulated by treatment with BMP2, an effect 
was dependent on cell type, and that silencing Noggin resulted in cell apoptosis. Our 
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results are in agreement with a number of studies in developmental biology. Loss of 
function Noggin transgenic mice present increased apoptosis during palatogenesis (157). 
Overexpression of Noggin in transgenic mice reduced apoptosis in eyelid epithelium 
(158) and during limb development (21). Noggin has also been found to regulate 
apoptosis during neural crest development (159). Interestingly, it has also been shown 
that the BMP inhibitor Sclerostin can also induce apoptosis in MSCs (160) and that 
administration of Gremlin during chick limb development inhibits apoptosis (161). In a 
clinical study, it was suggested that mRNA levels of BMP inhibitors during fracture 
healing might predict whether the facture will result in a non-union (64, 162, 163). These 
results demonstrate the complex regulation of BMPs and their inhibitors are critical in 
determining the final signaling outcome in tissue formation, regeneration, and 
homeostasis. 
While it is clear that BMP signaling regulates cell survival, the pathways by 
which this occurs are unclear. In our study, inhibitors to Smad signaling blocked BMP-
induced apoptosis in NHOst cells. Smad signaling also modulated apoptosis in colon 
cancer cells (164), but there is conflicting evidence on the pathway involved in osteoblast 
apoptosis. It has been suggested that this effect occurs through PKC-dependent, Smad-
independent signaling (148); however this study used dominant negative Smad1 
expression to establish this and did not examine the contributions of Smad 5 or 8. Here, 
we used dorsomorphin, which inhibits the ability of the BMP receptor to phosphorylate 
Smad1/5/8. Dorsomorphin is commonly used in the literature to inhibit canonical Smad-
BMP signaling, particularly during zebrafish embryogenesis (103, 165) but also during 
mammalian processes (104, 166). Several studies have reported that dorsomorphin (and 
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its analog LDN193189) may inhibit pathways other than BMP signaling (165, 167). 
However, the dose of dorsomorphin shown to inhibit these pathways in C2C12 cells was 
higher (500 nM) than in our study (168). There were no off-target effects demonstrated 
with 5 or 50 nM dorsomorphin, suggesting that the 10 nM dose used in this study may 
not induce off-target effects. 
CONCLUSIONS 
 Taken together, the results suggest that the effect of BMP2 treatment on 
osteoblast and progenitor apoptosis depends on the maturation state of the cell. While in 
progenitor cells BMP2 have minimal effects on cell apoptosis, in mature osteoblasts these 
potent factors induce apoptosis, especially at higher doses. The data suggest that in 
progenitor cells BMP2 acts more as a differentiation factor than an apoptogen and that in 
terminally differentiated cells, BMP2 induces apoptosis. It is possible that in clinical 
cases where complications arise with BMP2 administration, the osteogenic induction 





The objective of this study was to characterize the effect of BMP2 on regulation 
of inflammatory interleukin production and its relation to titanium implant surface 
roughness, and to determine the effect of BMP2 on osteoprogenitor and osteoblast 
apoptosis and the potential mechanism of action. The results of our study confirm the 
hypothesis that BMP2 affects interleukin production and induces apoptosis in osteoblasts, 
and elucidate the mechanisms of the complications seen clinically. 
The data demonstrate that material surface properties such as roughness and 
hydrophilicity are able to regulate osteoblast interleukin production, increasing anti-
inflammatory interleukins and reducing pro-inflammatory interleukins. These same 
surface features are known to induce osteoblast differentiation. The control of interleukin 
production by surface features may contribute to the shorter healing time seen with these 
same implants clinically, and demonstrate that interleukins play a major role in bone 
healing and osseointegration. However, co-administration of BMP2 with titanium 
implant insertion may produce adverse effects through TAB/TAK signaling by reversing 
the surface effect on the inflammation process, increasing pro-inflammatory interleukins. 
This deregulation of the inflammatory response may possibly delay bone formation. 
The effects on existing bone seen during clinical use of BMP2 may be a result on 
the differential effect of BMP2 on osteoprogenitor and osteoblast apoptosis. The results 
of this study indicate that the effect of BMP2 on progenitor and osteoblast apoptosis 
depends on the maturation state of the cell. In progenitor cells, BMP2 has minimal effects 
on cell apoptosis. However, in mature osteoblasts this morphogen induces apoptosis, an 
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effect dependent on dose. It is possible that in clinical cases where complications arise 
with BMP2 administration, the osteogenic induction effect in MSCs is less robust than 
the apoptosis induced in mature osteoblasts, resulting in osteolysis. Dose, location, and 
delivery strategies are important considerations in BMP2 as a therapeutic and must be 
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